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Abstract
Background: Recent studies showed that some of the dietary bioflavonoids can strongly stimulate the catalytic activity of
cyclooxygenase (COX) I and II in vitro and in vivo, presumably by facilitating enzyme re-activation. In this study, we sought to
understand the structural basis of COX activation by these dietary compounds.
Methodology/Principal Findings: A combination of molecular modeling studies, biochemical analysis and site-directed
mutagenesis assay was used as research tools. Three-dimensional quantitative structure-activity relationship analysis (QSAR/
CoMFA) predicted that the ability of bioflavonoids to activate COX I and II depends heavily on their B-ring structure, a
moiety known to be associated with strong antioxidant ability. Using the homology modeling and docking approaches, we
identified the peroxidase active site of COX I and II as the binding site for bioflavonoids. Upon binding to this site,
bioflavonoid can directly interact with hematin of the COX enzyme and facilitate the electron transfer from bioflavonoid to
hematin. The docking results were verified by biochemical analysis, which reveals that when the cyclooxygenase activity of
COXs is inhibited by covalent modification, myricetin can still stimulate the conversion of PGG2 to PGE2, a reaction
selectively catalyzed by the peroxidase activity. Using the site-directed mutagenesis analysis, we confirmed that Q189 at the
peroxidase site of COX II is essential for bioflavonoids to bind and re-activate its catalytic activity.
Conclusions/Significance: These findings provide the structural basis for bioflavonoids to function as high-affinity reducing
co-substrates of COXs through binding to the peroxidase active site, facilitating electron transfer and enzyme re-activation.
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Introduction
Cyclooxygenase (COX) I and II catalyze the metabolism of
arachidonic acid (AA), resulting in the formation of prostaglandins
(PGs), thromboxanes, and hydroxyeicosateraenoic acids (HETEs)
[1–4], which exert an array of important biological actions in the
body [5–7]. In humans, COX I and II share approximately 60%
overall sequence similarity, and the sequence homology in their
catalytic sites is even higher [8–10]. Whereas COX I is a
constitutively-expressed enzyme in most tissues and primarily
functions as a house-keeping enzyme, COX II is a highly-
inducible enzyme (such as in the presence of various mitogens) and
plays a critical role in mediating inflammation [11].
Both COX I and II have two catalytic activities that are
functionally coupled: one is to catalyze the cyclooxygenase
reaction that converts AA to prostaglandin G2 (PGG2), and the
other one is to catalyzes the peroxidase reaction that reduces
PGG2 to prostaglandin H2 (PGH2). These two reactions occur at
distinct but functionally-related catalytic sites. A branched-chain
model has been proposed to explain the mechanism of those two
reactions catalyzed by COX I and II [12]. Based on this model, a
peroxide (such as PGG2) is thought to initiate the peroxidase
reaction by abstracting two electrons from hematin in the
peroxidase active site, yielding Compound I, a protoporphyrin IX
(PPIX) radical cation with an oxyferry group (Fe
4+=O). Next,
Compound I undergoes an intra-molecular reduction by Tyr385 to
form Intermediate II with a neutral PPIX and a Tyr385 tyrosyl
radical. Alternatively, Compound I can undergo the one-electron
reduction by an exogenous electron donor, yielding Compound II
with a neutral PPIX and Tyr385. Intermediate II initiates the
cyclooxygenase reaction by abstracting one hydrogen atom from
arachidonic acid to yield an arachidonate radical, which then
reacts with two molecular O2 to produce PGG2.
Suicide inactivation is a known phenomenon of the COX
enzymes commonly observed during the catalysis of in vitro
reactions, resulting in the loss of the peroxidase and cyclooxygen-
ase activities in less than 1–2 min [13,14]. Mechanistically,
Intermediate II is thought to initiate the suicidal inactivation by
forming Intermediate III, which causes further unknown protein
modifications resulting in enzyme inactivation [13].
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bioflavonoids are strong activators of the catalytic activity of
COX I and II in vitro, in cultured cells, and also in vivo.I nt h i s
study, we sought to determine the structural basis and molecular
mechanism by which these bioflavonoids activate COX enzymes.
We jointly used the three-dimensional quantitative structure-
activity relationship/comparative molecular field analysis (3-D-
QSAR/CoMFA) and molecular docking approach, in combina-
tion with biochemical analysis and site-directed mutagenesis
studies. We found that some of the bioflavonoids can bind tightly
into the peroxidase active site and directly interact with the
hematin component of the COX enzymes to facilitate the
electron transfer from bioflavonoids to hematin. The findings of
this study provide the mechanistic understanding and structural
basis for bioflavonoids to function as high-affinity reducing co-
substrates/activators of COXs by interacting with hematin for re-
activation of the enzymes.
Results
QSAR/CoMFA analysis of the activation of the catalytic
activity of COX I and II by bioflavonoids
To probe the structural determinants of various bioflavonoids
for activating COX I and II, we developed the 3-D QSAR/
CoMFA models by using the experimental data obtained from 9
representative bioflavonoids (myricetin, quercetin, fisetin, morin,
baicalein, chrysin, apigenin, kaempferol and naringenin) and
flavone. These compounds were selected from our recent study
[15], and they all share a highly-similar core structure (structures
shown in Figure 1). In the QSAR/CoMFA analysis, the
experimental values are the COX I- or COX II-mediated
production of PGE2 (a major PG formed from AA) in vitro in the
presence or absence of a dietary compound [15]. The relevant
statistical parameters (PC, q
2, r
2, SEE, and F) for the CoMFA
models of COX I and II are listed in Figure 2. The contributions
from the steric and electrostatic fields were 42.5% and 57.5%,
respectively, for the COX I CoMFA model, and 56.7% and
43.3%, respectively, for the COX II CoMFA model. There is a
high degree of correlation between the experimentally-determined
values and the predicted values (Figure 2), with r
2 of 0.968 and
0.985, respectively, for COX I and II. In addition, the q
2 values
are 0.721 and 0.903, respectively. Since the q
2 values are far
greater than 0.5, it suggests that the 3-D QSAR/CoMFA models
developed in this study have a very high predictive ability.
The contour maps derived from the CoMFA models for COX I
and II are shown in Figure 3. Note that the quercetin molecule is
depicted inside COX I and II for demonstration. The contours of
the steric map are shown in yellow and green, and the contours of
the electrostatic map are shown in red and blue. Green contours
indicate regions where a steric bulkier substituent would increase
COX activity, whereas the yellow contours would indicate areas
where a steric bulkier substituent would decrease COX activity.
The red contours indicate regions where a substituent with stronger
negative charge would increase COX activity, whereas the blue
contours showed areas where a substituent with stronger negative
charge would decrease COX activity. There are a number of
similarities between the contour maps for COX I and II. Firstly,
the contour maps for both COX enzymes indicate the importance
of the negatively-charged substitutes around the 39,4 9 and 59
positions of B-ring for activating the catalytic activity of the COX
enzymes (Figure 3, red area). This suggestion is in agreement
with the observed higher ability of some of the compounds with
hydroxyl groups in their B-rings (such as myricetin) to stimulate
the COX activity as compared to compounds without hydroxyl
groups in their B-ring such as baicalein. In addition, the contour
maps also suggest that the negatively-charged substitutes near the
29 position of the B-ring may decrease the COX activity (Figure 3,
blue area). This suggestion also agrees well with the higher
stimulation of the COX activity by quercetin (with hydroxyl
groups at the 3, 5, 7, 39 and 49 positions) compared to morin (with
hydroxyl groups at 3, 5, 7, 29 and 49 positions). Furthermore, the
contour maps predict that a bulker substitute near the 39 position
would increase the COX activity (Figure 3, green area).
Molecular modeling analysis of the binding interactions
of bioflavonoids with COX I and II
The 3-D structural models of the human COX I and II were
successfully built using the Modeler program in InsightII according to
the known x-ray structures of the sheep COX I (PDB code: 1diy)
and mouse COX II (PDB code: 1dcx), respectively, as templates.
As shown in Figure 4A, only two candidate binding sites (named
as SITE-1 and SITE-2) were predicted by the Active-Site-Search
function of the Binding-Site module in InsightII.S ITE-1 was located
in the N-terminus of the COX proteins, which is part of the
Figure 1. Chemical structures of the bioflavonoids used in this study. The structure of flavone is enlarged to show the numbering of
different carbon positions.
doi:10.1371/journal.pone.0012316.g001
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reality, this site would not be accessible by the highly hydrophilic
bioflavonoids. SITE-2 is located close to the hematin structure and
far away from the membrane, which is actually the known
peroxidase catalytic site [3]. The Simulated-Annealing function in the
Docking module was then used to dock quercetin into SITE-2. The
binding pocket was defined to include amino acid residues within a
4-A ˚ reach around SITE-2. One hundred docking modes were
calculated and the conformation with the lowest energy value was
then further minimized. Figure 4B and 4C show the docked
structures of quercetin in the peroxidase catalytic sites of COX I
and II, respectively. Notably, quercetin was found to bind inside a
rather deep binding pocket in both COX I and II, which is
immediately next to hematin. The docking models predict that the
binding site in COX I is relatively deeper than that in COX II,
partly due to the different loop structures (composed of amino acid
residues 181–190 for COX I and 167–176 for COX II) of these
two enzymes.
Our recent study showed that quercetin and myricetin have a
high potency for activating the COX activity in cultured cells, with
an apparent EC50 value of approximately 50 nM [15]. As shown
in Figure 4D and 4E, several hydrogen bonds are formed
between quercetin, hematin and the amino acid residues in the
binding sites, which would be in line with its high binding affinity
for the COX enzymes. For COX I, one hydrogen bond is formed
between quercetin and hematin and four hydrogen bonds are
formed between quercetin and amino acid residues E290, H207
and F200. For COX II, three hydrogen bonds are formed between
quercetin and amino acid residues Q189 and H193.
By using the same method, we also docked myricetin, chrysin
and flavone into the enzyme binding pockets of COX I and II.
The binding energy values for all four ligands are summarized in
Table 1. Notably, myricetin has one more hydroxyl group in its
B-ring than does quercetin, and its binding energy values for COX
I and II are lower than those of quercetin. This information led to
the suggestion that myricetin has a higher binding affinity for
COX I and II than quercetin, which agrees with our earlier study
[15] showing that myricetin reached the stimulation plateau at
lower concentrations than quercetin.
Notably, chrysin and flavone have no hydroxyl groups in their
B-rings, but they could still bind to the same binding sites of the
COX enzymes with relatively-lower binding affinities compared to
myricetin and quercetin. Because of these structural and
pharmacological features, it is predicted that these two bioflavo-
noids may be able to function as antagonists that would block the
binding of the bioactive co-substrates (such as quercetin and
myricetin) to the catalytic active sites and thus reduce their
stimulation of the COX enzymes. This mechanistic explanation is
supported by the observation made in our recent study [15]
showing that flavone could suppress, in a concentration-dependent
manner, the COX II-mediated formation of PGs in LPS-
pretreated RAW cells [15].
Experimental results in support of the docking models
Biochemical analysis. To provide experimental evidence
for the computational model that bioflavonoids can stimulate the
catalytic activity of COXs by binding to the peroxidase site but not
the cyclooxygenase site, we studied the stimulatory effect of
myricetin (a representative bioflavonoid) on the catalytic activity of
COX I and II pretreated with aspirin, which can covalently
acetylate and thereby inactivate the cyclooxygenase active site in
these enzymes. To selectively test the effect of myricetin on the
peroxidase activity of COX enzymes, PGG2 was used as a
substrate to bypass the cyclooxygenation step (i.e., the conversion
of AA to PGG2). As shown in Figure 5A and 5D, pretreatment of
COX I and II with aspirin (0.5 and 5 mM, respectively) strongly
inhibited the cyclooxygenase activity by 72% and 70%,
respectively, when [
14C]AA was used as substrate. However,
when PGG2 was used as substrate, aspirin-pretreated COX I and
II did not exert the same level of inhibition of their COX activity,
which was as expected.
Figure 2. The 3-D QSAR/CoMFA analysis showing the correla-
tion between the experimentally-determined COX-stimulating
activity values and the predicted values. Nine representative
bioflavonoids plus flavone were used in the analysis. The experimental
values were based on measuring PGE2 production, which was
determined in our previous study [15]. Statistical parameters (q
2, r
2,
PC, SEE, and F) for the CoMFA models of COX I and II are also listed in
the figure.
doi:10.1371/journal.pone.0012316.g002
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COX I and II (without aspirin pretreatment) was activated by 5-
and 8-fold, respectively, when [
14C]AA was the substrate
(Figure 5B and 5E). When PGG2 was used as substrate (as
shown in Figure 5C and 5F), myricetin stimulated the catalytic
activity of COX I and II that were either pretreated with aspirin or
received no pretreatment to a similar extent. Furthermore, the fold
of stimulation was similar to what was seen with untreated COX I
and II when [
14C]AA was used as substrate (Figure 5B and 5E).
Taken together, these data clearly show that myricetin activates
COX I and II through interaction with the peroxidase site but not
the cyclooxygenase site. Notably, at higher concentrations of
myricetin (500 and 1000 mM), the catalytic activity of COX I and
II was inhibited to a similar degree, regardless of whether or not
the enzymes were pretreated with aspirin. This additional
observation indicates that the inhibition of the COX activity by
high concentrations of bioflavonoids is due to the inhibition of the
peroxidase catalytic activity.
Mutagenesis studies. To confirm the binding models
obtained from our molecular docking studies showing that
hydrogen bonds are formed between a bioflavonoid molecule
and the amino acid residues Q189 and H193 of COX II
(Figure 4E), we used the site-directed mutagenesis approach to
verify the functional role of these two amino acid residues. We first
made the Q189A, H193A and Q189A/H193A mutant proteins of
COX II (expressed in cos-7 cells), and their levels of expression
were confirmed using Western blot analysis (data not shown). As
summarized in Table 2, the catalytic activity of the Q189A,
H193A and Q189A/H193A mutant proteins was approximately
32%, 10.2% and 0% of the wild-type COX II activity. This
observation showed that H193 played a more important role than
Q189 in catalyzing the peroxidation reaction of the substrate. As
shown in Table 2, myricetin could not stimulate the catalytic
activity of the Q189A and H193A mutants, instead it inhibited
their activity. Because the H193 mutant lost most of the catalytic
activity, we chose to further study the interaction of Q189 with
bioflavonoids by designing three additional mutant COX II
proteins, i.e., Q189E, Q189N and Q189R. Glutamic acid (E) is
structurally very similar to glutamine (Q) with the same side-chain
length and similar side-chain functional groups. Based on our
docking model, we expected that the Q189E mutant likely would
be able to bind bioflavonoids in a similar way as the wild-type
COX II. In comparison, asparagine (N) has the same side-chain
functional group but one carbon shorter than glutamine (Q),
whereas arginine (R) has a positive-charged side chain compared
with the relatively acidic side chain of glutamine (Q). As
summarized in Table 2, Q189E and Q189N mutants retained
approximately 80% and 56%, respectively, of the catalytic activity
of the wild-type COX II, whereas Q189R retained approximately
30% of the catalytic activity. As we expected based on the docking
models, myricetin could still stimulate the catalytic activity of the
Q189E mutant by 51.4% over the corresponding control, but it
did not stimulate the catalytic activity of the other two mutant
enzymes (Q189N and Q189E), instead it inhibited their catalytic
activity by 32.9% and 38.8%, respectively.
Discussion
In the present study, we conducted computational molecular
modeling study and biochemical analysis to probe the mechanism
of COX activation by dietary bioflavonoids. Data from the 3-D
QSAR/CoMFA study predict that the B-ring of bioflavonoids play
an important role for their direct activation of the catalytic activity
of COX I and II. This notion is also supported by data from our
Figure 3. The 3-D QSAR/CoMFA color contour maps for COX I (A) and COX II (B). Note that quercetin was shown in the ball and stick format
inside the field for demonstration. Oxygen, carbon, and hydrogen atoms are colored in red, gray, and blue, respectively. The contours of the steric
maps are shown in yellow and green, and those of the electrostatic maps are shown in red and blue. Green contours indicate regions where a
relatively bulkier substitution would increase the COX activity, whereas the yellow contours indicate areas where a bulkier substituent would
decrease the COX activity. The red contours are regions where a negative-charged substitution likely would increase the COX activity whereas the
blue contours showed areas where a negative-charged substitution would decrease the COX activity. Bioflavonoids with a higher ability to activate
the COX enzymes are correlated with: (i) more bulkier substitute near green; (ii) less bulkier substitute near yellow; (iii) less negative charge near blue;
and/or (iv) more negative charge near red. The figure in the lower panel shows the 90u rotation around the x-axis of the figure shown in the upper
panel.
doi:10.1371/journal.pone.0012316.g003
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peroxidase active site and directly interact with hematin, thereby
facilitating the electron transfer from bioflavonoids to hematin.
Additional biochemical analyses showed that when PGG2 is used
as substrate, bioflavonoids can stimulate, to a similar degree, the
catalytic activity of COX I and II with or without aspirin
pretreatment of the enzymes. Furthermore, the site-directed
mutagenesis analysis of the COX II enzyme confirmed the
prediction of the docking model suggesting that Q189 in the
peroxidase active site is important for the binding interaction with
bioflavonoids and, subsequently, the stimulation of the COX II
catalytic activity. Taken together, these data provide a rather
detailed explanation of the molecular mechanism and structural
basis for certain bioflavonoids to function as reducing co-substrates
for the COX enzymes.
The structure-activity relationship regarding the antioxidant
activity of various bioflavonoids has been extensively studied in the
past [17–20]. Their antioxidant activity depends heavily on the
Figure 4. Identification of the binding sites for COX I and II by molecular docking approach. A. The superimposed structures of COX I and
II in complex with hematin and AA. The white labels indicate the two potential binding sites for quercetin as identified by the Active-Site-Search
function in InsightII. B. Docking results for quercetin in SITE-2 of COX I. C. Docking results for quercetin in SITE-2 of COX II. D. Enlarged view of the
interaction of quercetin with hematin and key amino acid residues in the peroxidase active sites of COX I. E. Enlarged view of the interaction of
quercetin with hematin and key amino acid residues in the peroxidase active site of COX II. The protein structure was shown in the ribbon format in
A, B and C. COX I was colored in pink and COX II in purple. AA was colored in light green for COX I and dark green for COX II. Quercetin was colored
in light red for COX I and magenta for COX II. Carbon atoms in hematin were colored in yellow for COX I and orange for COX II whereas nitrogen
atoms were colored in blue, oxygen atoms in red, and magnesium in silver. The green dashes represent the hydrogen bonds. Hematin, AA, key amino
acid residues, and quercetin are shown in the ball and stick format. For amino acid residues, oxygen atoms are shown in red, carbon atoms in gray,
and nitrogen atoms in blue. Hydrogens are omitted in these molecules.
doi:10.1371/journal.pone.0012316.g004
Table 1. The computed binding energy values (DEbinding) for
the molecular docking study for the binding of myricetin,
quercetin, chrysin or flavone with human COX I or COX II.
Bioflavonoids COX I DEbinding (kcal/mol) COX II DEbinding (kcal/mol)
Myricetin 2109.23 2178.65
Quercetin 283.50 2156.20
Chrysin 240.33 295.25
Flavone 266.66 288.32
The ligand-enzyme interaction energy value (DEbinding) was calculated using the
following equation: DEbinding=Ecomplex2(ECOX+Eligand), where Ecomplex was the
potential energy for the complex of COX bound with the ligand, ECOX was the
potential energy of the enzyme alone, and Eligand was the potential energy for
the ligand alone.
doi:10.1371/journal.pone.0012316.t001
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14C]AA or PGG2 is
used as substrate. The incubation mixtures consisted of 20 mM[
14C]AA (0.2 mCi) or 10 mM PGG2 as substrate, COX I or COX II as enzyme (0.5 or
0.97 mg/mL, respectively), 10 mM EDTA, 1 mM reduced glutathione, 1 mM hematin, and myricetin in 200 mL Tris-HCl buffer (100 mM, pH 7.4). The
reaction was incubated at 37uC for 5 min and terminated by adding 15 mL of 0.5 N HCl to each test tube. Ethyl acetate (600 mL) was added
immediately for extraction. The dried extracts were re-dissolved in acetonitrile or EIA buffer (Cayman Co. Michigan, USA), and the metabolites were
analyzed using HPLC (with radioactivity detection) when [
14C]AA was used as substrate [15] or using an EIA kit when PGG2 was used as substrate.
Note that in this experiment, the COX I and II enzymes with or without aspirin pretreatment were both tested. For aspirin pretreatment, enzymes
were pre-incubated with aspirin at 0.5 mM for COX I or 5 mM for COX II for 30 min at room temperature and then were immediately used as the
enzyme source in the assay.
doi:10.1371/journal.pone.0012316.g005
Table 2. The catalytic activity of several COX II mutants assayed in the presence or absence of myricetin.
Enzyme COX II catalytic activity (formation of PGF2a + PGE2 + PGD2; % of control)
Without myricetin With 100 mM myricetin
Wild-type 100 224.5 (q 124.5%)
a
Q189A 32.0 11.5 (Q 74.1%)
H193A 10.2 N.D. (Q 100%)
Q189A/H193A N.D.
b N.D.
Q189E 78.5 118.9 (q 51.4%)
Q189N 55.9 37.3 (Q 32.9%)
Q189R 37.9 23.2 (Q 38.8%)
The catalytic activity of COX II enzyme was based on measuring the formation of PGF2a+PGE2+PGD2 from [
14C]AA as substrate.
aThe number in parenthesis represents the % of increase or decrease over the corresponding control (in the absence of myricetin).
bN.D., not detected.
doi:10.1371/journal.pone.0012316.t002
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in the molecules. The presence of a catechol structure (39,49-
dihydroxyls) in the B-ring and a 2,3-double bond in the C-ring
are important determinants for the high antioxidant activity [17–
19]. The presence of 3- and 5-dihydroxyl groups usually further
enhances the antioxidant activity. By comparing the stimulation
of COX activity by apigenin and naringenin (Figure 2), we can
see that the 2,3-double bond in the C-ring is an essential structure
for bioflavonoids to have a stimulatory effect on the COX
activity, although this point was not suggested by our CoMFA
contour maps. The considerable similarity noted between our 3-
D QSAR/CoMFA models and the earlier observations on the
antioxidant activity of various bioflavonoids suggests that the
ability of various bioflavonoids to directly stimulate the COX
catalytic activity is, in a large part, attributable to their
antioxidant property.
The molecular docking studies identified that bioflavonoids can
bind to the peroxidase sites of COX I and II, thus suggesting the
possibility that bioflavonoids stimulate their catalytic activity by
interacting with the peroxidase sites. This suggestion was
confirmed by biochemical analysis using PGG2 as substrate to
bypass the cyclooxygenase reaction. Our observation that
myricetin can stimulate the catalytic activity of COX enzymes to
a similar degree with either PGG2 or AA as a substrate provides
support for the notion that myricetin selectively activates the
peroxidase activity. Our additional observation showing the lack of
an effect of the aspirin pretreatment of the COX enzymes on
myricetin’s ability to activate their peroxidase activity (assayed
using PGG2 as substrate) provides definitive evidence for this
suggestion.
Our findings from our homology modeling and molecular
docking studies provide detailed insights on the molecular
mechanism of actions. As shown in Figure 4, bioflavonoids can
fit into the peroxidase sites of COX I and II tightly and form
several hydrogen bonds with the hematin moiety as well as with
the nearby amino acid residues (in the case of quercetin, E290,
H207 and F200 for COX I; H193 and Q189 for COX II). The
formation of these hydrogen bonds facilitates the electron transfer
from the B-ring of a bioflavonoid molecule to the hematin element
of the enzymes. The binding energy values calculated from the
docking models correlate well with the ability of the active
bioflavonoids to stimulate the catalytic activity of the COX
enzymes, which provides additional support for the docking
models.
In addition, the docking model of COX II is also supported by
the results of our site-directed mutagenesis studies. By mutating
Q189 and H193 into alanine (A), we showed that Q189 and
H193 are important for COX II activity, especially the
peroxidase activity, which is consistent with an earlier report
[21]. H193 plays a more important role than Q189 since the
H193A mutant nearly loses all catalytic activity compared to the
Q189A mutant. The observation that myricetin cannot activate
the Q189A, Q189N, or Q189R mutant COX II enzyme revealed
that the side chain of Q189 is vitally important for the binding
interaction with bioflavonoids and also for their stimulation of the
COX II activity. This experimental observation confirms our
docking results showing that Q189 forms two hydrogen bonds
with bioflavonoids (Figure 4E). As expected, the Q189E mutant
can still be stimulated by myricetin because the side chain of
glutamic acid (E) is of the same length and similar chemical
property as the side chain of glutamine (Q), and thus hydrogen
bonds can still be formed between glutamic acid and bioflavo-
noids. Although approximately 56% of the catalytic activity is
retained in the Q189N mutant protein, myricetin cannot
stimulate its catalytic activity, which indicates that the length of
the side chain of Q189 is crucial for binding interactions with
bioflavonoids.
There were several earlier studies that investigated a number of
reducing co-substrates of COXs [22–26]. The mechanism is
generally thought to be due to the reduction of the oxidized
intermediates by the co-substrates [23,25]. As depicted in
Figure 6, the reducing potential of bioflavonoids, like other
reducing co-substrates, will help maintain the peroxidase cycle
and thereby slow down the suicidal inactivation of the COX
enzymes by donating one electron each to Compound I and II to
restore the reducing activity of hematin, which is needed for the
peroxidase to convert PGG2 to PGH2. The oxidized quinone
form of bioflavonoids is expected to have a lower binding affinity
for the peroxidase site because they will lose two hydrogen bond
donors (hydroxyl groups), and some of the hydrogen bonds
cannot be formed between the quinine form and the peroxidase
site. Accordingly, the following catalytic sequence is proposed
(depicted in Figure 6): It is assumed that PGG2 has a high
binding affinity for the peroxidase site of the enzyme and will
tightly bind to this site. Immediately following the catalytic
conversion of PGG2 to its product, the product will dissociate
from the enzyme (due to a reduced binding affinity). After that,
the peroxidase site will become catalytically inactive (with an
oxidized hematin), and it will be bound by a bioflavonoid
molecule (in its reduced form) for the reduction of hematin to its
initial state. During the process, the bioflavonoid is oxidized
initially to semiquione (as an intermediate) and then to quinone.
The bioflavonoid quinone will then be released from the
activated peroxidase site because the oxidized molecule will have
a reduced binding affinity for the peroxidase active site. In this
model, it is apparent that there is a potential competition between
the substrate (PGG2) and the co-substrate (bioflavonoid) at the
peroxidase catalytic site. When the bioflavonoid concentration
becomes too high, it will increase the fraction of the active
peroxidase site that is still occupied by the reducing co-substrate,
and when this occurs, it would inhibit the binding of PGG2 to the
peroxidase site and thus would reduce the catalytic activity of the
enzyme for the formation of further products. This mechanistic
explanation is in agreement with the data shown in Figure 5C
and 5F as well as a number of earlier studies showing a
concentration-dependent biphasic modulation of the COX
activity by co-substrates, namely, the presence of a co-substrate
at low concentrations stimulated the COX activity, whereas its
presence at higher concentrations inhibited the COX activity
[22–28]. Notably, some of the earlier studies suggested that the
inhibition by high concentrations of the co-substrate was due to
the fast reduction of Intermediate II and the loss of cyclooxygenase
activity [27]. This explanation appears to disagree with the
observation (in Figure 5C and 5F) made in this study which
showed that myricetin at high concentrations (500 and 1000 mM)
inhibited the peroxidase activity of aspirin-pretreated COX II
(using PGG2 as substrate) to a similar degree as they inhibited the
catalytic activity of untreated COX II enzyme for its metabolism
of AA as substrate.
In conclusion, the results of our present study show that some of
the bioflavonoids can bind tightly to the peroxidase active site of
the COX enzymes, and through direct interaction with hematin,
the electrons are transferred from the bioflavonoid molecule to
hematin, ultimately facilitating the re-activation of the COX
enzymes during a catalytic cycle. The ability of bioflavonoids to re-
activate the COX catalytic activity depends heavily on the
structural features of their B-rings and their overall antioxidant
activity.
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Chemicals and reagents
[
14C]Arachidonic acid ([
14C]AA, specific radioactivity of
53 Ci/mol) was purchased from PerkinElmer (Boston, USA).
Myricetin, aspirin, Dulbecco’s modified Eagle’s medium (DMEM)
and fetal bovine serum (FBS) were purchased from Sigma-Aldrich
Co. (St. Louis, MO). Human COX I and II, PGG2, and enzymatic
immunoassay (EIA) kit for PGE2 were purchased from Cayman
(Ann Arbor, Michigan). According to the supplier, the COX I and
II preparations used in this study had a purity of approximately
95% and 70%, respectively. The cDNA of the human COX II was
purchased from Origene Technologies (Rockville, MD). Quik-
Change XL site-directed mutagenesis kit and XL10-Gold
competent cells were purchased from Stratagene (La Jolla, CA).
QIAprep miniprep kit was obtained from Qiagen (Valencia, CA).
Lipofectamine-2000 and goat anti-rabbit IgG conjugated to
horseradish peroxidase were purchased form Invitrogen Co.
(Carlsbad, CA). Polyclonal rabbit antibody against COX II was
purchased from Cell Signaling Technology, Inc. (Danvers, MA).
Cos-7 cells were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). The ECL Plus kit was
purchased from GE Healthcare Bio-Sciences Corp. (Piscataway,
NJ).
Quantitative structure-activity relationship (QSAR)
analysis
All calculations described in this study were carried out using
the SYBYL molecular modeling program (V7.1, Tripos Inc., St.
Louis, MO) installed in a Red Hat Enterprise Linux WS4.0 (Red
Hat Inc. Raleigh, NC) operating system on a Dell Precision 690
workstation.
Molecular models and structural alignment. The
chemicals used in this study comprised of a total of nine
bioflavonoids (myricetin, quercetin, fisetin, morin, baicalein,
chrysin, apigenin, kaempferol, and naringenin) plus flavone
(structures shown in Figure 1). All molecules were constructed
using the building tools of the SYBYL7.1 molecular modeling
software. The geometry of each molecule was optimized using
the standard Tripos force field with the conjugate-gradient
minimization to an energy change convergence criterion of
0.001 kcal/mol. All atomic partial charges were computed using
the Gasteiger-Marsili method. All molecules were aligned to
flavone as a template by using the rigid-body least-squares
fitting method. After alignment, the molecules were placed in a
3-D cubic lattice with 2-A ˚ spacing. If the calculated steric and
electrostatic energy values were .30 kcal/mol, they were
truncated to this value, an empirical approach that has been
adopted in many similar studies [29].
3-D QSAR/CoMFA analysis. For 3-D QSAR/CoMFA
analysis, the method of partial least squares (PLS) regression was
used to analyze the compounds by correlating the experimentally-
determined COX activity and the computed values according to
the CoMFA fields. The experimental values were adopted from
our recent study [15], and they refer to the fold of stimulation of
PGE2 production in vitro when 200 mM of a given flavonoid was
present. In this study, we used one representative concentration
(200 mM) of each bioflavonoid because our earlier analysis of
concentration dependence showed that myricetin, quercetin,
fisetin and morin (representative bioflavonoids tested) exerted
Figure 6. Schematic depiction of the catalysis and inactivation mechanism of COX enzymes and their interaction with
bioflavonoids. PPIX is for protoporphorin IX. Quercetin structure is shown as a representative bioactive bioflavonoid. Events in the peroxidase cycle
are labeled with numbers to denote the sequence of occurrence.
doi:10.1371/journal.pone.0012316.g006
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this concentration [15]. Accordingly, the magnitude of peak
stimulation was adopted to reflect the relative stimulatory efficacy/
capacity of each bioflavonoid. In addition, we showed that when
[
14C]AA was used as substrate, the production of PGF2a, PGE2,
PGD2 and 12-HHT was stimulated almost in a parallel manner
when different concentrations of these bioflavonoids were present
[15]. Based on these observations, we thus chose to use the
formation of PGE2 as a representative product to conveniently
reflect the COX catalytic activity in vitro.
The first PLS analysis was done to determine the optimum
number of the principal components (PCs) by using the leave-one-
out cross-validation procedure. In this method, each compound
was systematically excluded once from the data set, after which its
activity was predicted by a model derived from the remaining
compounds. The q
2 value (i.e., the cross-validated correlation
coefficient value) was calculated based on these predictions in the
first PLS analysis, and this parameter generally assesses a model’s
predictive ability. By setting the number of PCs to the optimum
number, the second PLS analysis was carried out without cross-
validation to calculate the correlation coefficient r
2. The r
2
generally reflects a model’s overall goodness of fit to the
experimentally-determined values for the compounds. In most
studies, a model with r
2.0.9 and q
2.0.5 is generally considered to
be of acceptable predictive ability.
Molecular docking of bioflavonoids into the binding
pockets of COX I and II
Energy minimization and molecular docking were performed
on a Dell Precision 690 workstation using the InsightII modeling
software (Version 2005, Accelrys Inc. San Diego, CA) installed in a
Red Hat Enterprise Linux WS4.0 operating system. The CVFF
force field was used for energy minimization with Polak and Ribiere
conjuate gradients until the final convergence criterion reached
the 0.001 kcal/molA ˚. The structures of quercetin, myricetin and
chrysin were built with the Builder module in InsightII and
minimized with the Discover module.
Homology modeling. Since the x-ray structures of human
COX I and II are not available at present, the sheep COX I
structure (PDB code: 1diy [30]) and mouse COX II model (PDB
code: 1dcx [31]) in complex with AA were used as templates to
build the homology models of human COX I and II. Protein
sequence analysis showed that the similarity between the sheep
COX I (GI: 57164169) and human COX I (GI: 243972) is
93.85%, and the similarity between the mouse COX II (GI:
31981525) and human COX II (GI: 38565065) is 86.76%. Given
the high degrees of their sequence similarity, we thus directly used
the Modeler module of InsightII to generate five 3-D structure
models for both human COX I and II. The models for COX I and
II with the optimal side chain conformation and lowest potential
energy were chosen for further minimization. Notably, because the
hematin structure was missing in the mouse COX II (PDB code:
1dcx) model, another x-ray structure of the mouse COX II (PDB
code: 5cox [32]) was used for superimposition with the 1dcx
structure, and the precise positioning of hematin in the 5cox
structure was adopted to the 1dcx structure and the whole
structure was further minimized using Molecular Dynamics (a module
in InsightII Discover 3) with the backbone of the protein held fixed.
Binding site determination and molecular docking. The
binding sites on the COX enzymes for bioflavonoids were
determined by using the Active-Site-Search function in the Binding-
Site module of InsightII. The site-open-size parameter was set at 7 A ˚
and the site-cut-off-size parameter was set at 420 A ˚ 3 based on the
size of quercetin (12 A ˚65A ˚67A ˚). We defined the binding pocket
with amino acid residues within 4 A ˚ around the candidate binding
sites. Simulated Annealing docking method in the Affinity module was
used to dock each bioflavonoid molecule into the candidate
binding pockets. One hundred docking modes were calculated and
the ones with the lowest binding energy were chosen for further
minimization. The interaction energy (DEbinding) value between a
given compound and the enzyme was calculated by using the
following equation: DEbinding=Ecomplex2(ECOX+Eligand), where
Ecomplex was the potential energy for the complex of COX
bound with the ligand, ECOX was the potential energy of the
enzyme alone, and Eligand was the potential energy for the ligand
alone. The interaction energy was used to estimate the relative
interaction affinity between the enzyme and the dietary
compound.
Selective inhibition of the cyclooxygenase activity of COX
I and II
Earlier studies showed that aspirin can selectively and covalently
modify the cyclooxygenase active site (but not the peroxidase
activity site), resulting in a selective knockout of the cyclooxygen-
ase activity of the COX enzymes [33–35]. This approach was
adopted in the present study, and the COX I and II enzymes were
pre-incubated with aspirin (at 0.5 and 5 mM, respectively) for
30 min at room temperature.
For measuring the catalytic activity of untreated control COX I
or COX II,
14C-AA was used as substrate, but for measuring the
catalytic activity of aspirin-pretreated COX I or COX II, PGG2
was used as substrate. The reason that we used PGG2 as a
substrate for the aspirin-pretreated COXs was because it is the
intermediate product of AA formed by the cyclooxygenase activity
of COXs, and it can still be further converted to form PGH2 by
the peroxidase activity of the COXs. PGH2 can be further
converted non-enzymatically to PGF2a, PGE2, and PGD2.
Although the decomposition may be differentially affected by the
presence of myricetin, our recent study [15] showed that when
[
14C]AA was used as substrate, the production of PGF2a, PGE2
and PGD2 catalyzed by COX I or COX II was stimulated almost
in a parallel manner when different concentrations of myricetin
were present. Therefore, measuring the changes in the sum of
these PG products or in PGE2 alone was used as indicators of the
changes in PGH2 level or the peroxidase activity of COXs.
Experimentally, the incubation mixtures (in Eppendrof tubes)
included the following: 20 mM
14C-AA (0.2 mCi) or 10 mM PGG2
as substrate, COX I or COX II as the enzyme (0.5 or 0.97 mg/
mL, respectively), 10 mM EDTA, 1 mM reduced glutathione,
1 mM hematin, and myricetin in a final volume of 200 mL Tris-
HCl buffer (100 mM, pH 7.4). Myricetin was initially dissolved in
pure ethanol as stock and then further diluted with the reaction
buffer. The reaction was incubated at 37uC for 5 min and
terminated by adding 15 mL of 0.5 N HCl to each tube. Ethyl
acetate (600 mL) was added immediately for extraction. When
[
14C]AA was used as substrate, the dried extracts were re-dissolved
in acetonitrile for analysis of representative PG products by
HPLC, and when PGG2 was used as substrate, the dried extracts
were re-dissolved in the EIA buffer for analysis of PGE2 using an
EIA kit.
Since PGG2 may spontaneously decompose to PGH2 and then
to other PGs (such as PGE2), here we also assessed the stability of
PGG2 under the above in vitro reaction conditions. We incubated
PGG2 at 37uC for 5 min in the same reaction buffer as described
above (in the absence of the COX enzyme), and we found that less
than 0.01% of PGG2 was spontaneously converted to PGE2 after a
5-min incubation at 37uC. Also, the presence of 100 mM myricetin
Co-Substrates of COX I and II
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spontaneous conversion of PGG2 to PGE2.
In vitro site-directed mutagenesis study
The human COX II cDNA was used as template to generate
the corresponding mutant cDNAs used in this study. The site-
directed mutagenesis of the COX II gene in vitro was performed
using a PCR-based QuikChange XL site-directed mutagenesis kit
according to the procedures recommended by the manufacturers.
The primers used for site-directed mutagenesis are listed in
Table 3. The reconstructed plasmids were purified from the
transformed XL10-Gold using the QIAprep Miniprep kit.
Sequences of all reconstructed plasmid DNAs were confirmed
by DNA sequencing. Cos-7 cells were maintained in DMEM
supplemented with 10% FBS and used to express the wild-type
and mutant COX II proteins. The transfection of reconstructed
mutant plasmids was carried out using Lipofectamine-2000
according to the manufacturers’ instructions.
Thirty h after transfection with the plasmids, cells were collected
by centrifugation and were then sonicated in ice-cold lysis buffer
(50 mM Tris-HCl and 200 mM NaCl, pH 7.5). After addition of
5 mM 1,4-dithiothreitol and 1 mM phenylmethylsulfonyl fluoride
(PMSF) to the crude homogenates, they were centrifuged at
10,0006g for 10 min at 4uC. After addition of 10% glycerol, the
supernatants were stored at 280uC until they were used as enzyme
source for assaying the COX II’s catalytic activity. Western blot
analysis was used to determine the expression of the wild-type and
mutant human COX II proteins, which were separated by using
the 10% SDS-polyacrylamide gel (SDS-PAGE) in a Mini-Protein
system (BioRad, Hercules, CA). After electrophoresis, the protein
bands on the gel were transferred onto PVDF membrane (BioRad,
Hercules, CA). The membrane was first blocked with 5% non-fat
dried milk powder in Tris-HCl-buffered saline containing 0.1%
Tween-20 (the blocking solution), and then probed with polyclonal
rabbit antibodies against COX II. The primary antibody-antigen
complexes were detected using the goat anti-rabbit IgG conjugat-
ed to horseradish peroxidase and developed by using the ECL Plus
kit.
The COX catalytic activity was assayed as described above, by
using the whole cell lysates as the enzyme source and [
14C]AA as
the substrate. Measuring the combined formation of PGF2a, PGE2
and PGD2 was used to reflect the COX II catalytic activity.
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